Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3987791,half life,The elimination profile of the drug showed that the half life of the unchanged drug ranged between 1 and 2 h except in one subject with a half-life of about 4 h.,Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987791/),h,1 and 2,7942,DB01171,Moclobemide
,3987791,half-life,The elimination profile of the drug showed that the half life of the unchanged drug ranged between 1 and 2 h except in one subject with a half-life of about 4 h.,Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987791/),h,4,7943,DB01171,Moclobemide
,3987791,F,"The mean bioavailability calculated using flow model concepts was F = 0.43 after 50 mg, F = 0.47 after 100 mg and F = 0.59 after 200 mg.",Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987791/),,0.43,7944,DB01171,Moclobemide
,3987791,F,"The mean bioavailability calculated using flow model concepts was F = 0.43 after 50 mg, F = 0.47 after 100 mg and F = 0.59 after 200 mg.",Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987791/),,0.47,7945,DB01171,Moclobemide
,3987791,F,"The mean bioavailability calculated using flow model concepts was F = 0.43 after 50 mg, F = 0.47 after 100 mg and F = 0.59 after 200 mg.",Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987791/),,0.59,7946,DB01171,Moclobemide
,3987791,t 1/2,The outlier with a t 1/2 of 4 h was found to have a bioavailability of more than 0.80 after all 3 doses.,Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987791/),h,4,7947,DB01171,Moclobemide
more,3987791,bioavailability,The outlier with a t 1/2 of 4 h was found to have a bioavailability of more than 0.80 after all 3 doses.,Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987791/),,0.80,7948,DB01171,Moclobemide
,1347659,sensitivity factor,"The tyramine sensitivity factor at 2 h after dosing was about 2.1, with no significant differences between the doses used.",Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1347659/),,2.1,8282,DB01171,Moclobemide
,9174681,half-life,Plasma kinetics of esuprone showed a rapid elimination with a half-life of about 4 h.,"MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174681/),h,4,42253,DB01171,Moclobemide
less,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,24,56611,DB01171,Moclobemide
,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),d,2,56612,DB01171,Moclobemide
,7834966,tmax,"All 3 of the structurally unique newer antidepressants [amfebutamone (bupropion), viloxazine venlafaxine] have relatively short tmax values (1 to 2 hours), which may relate to the early onset of adverse effects.",Pharmacokinetic optimisation of therapy with newer antidepressants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,1 to 2,56613,DB01171,Moclobemide
,2297459,Cmax,"Cmax, tmax and t1/2 for moclobemide were (mean +/- s.d.) 2.70 +/- 1.24 mg l-1, 2.03 +/- 1.19 h and 2.26 +/- 0.26 h, respectively.",Moclobemide excretion in human breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297459/),[mg] / [l],2.70,83132,DB01171,Moclobemide
,2297459,tmax,"Cmax, tmax and t1/2 for moclobemide were (mean +/- s.d.) 2.70 +/- 1.24 mg l-1, 2.03 +/- 1.19 h and 2.26 +/- 0.26 h, respectively.",Moclobemide excretion in human breast milk. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297459/),h,2.03,83133,DB01171,Moclobemide
,2297459,t1/2,"Cmax, tmax and t1/2 for moclobemide were (mean +/- s.d.) 2.70 +/- 1.24 mg l-1, 2.03 +/- 1.19 h and 2.26 +/- 0.26 h, respectively.",Moclobemide excretion in human breast milk. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297459/),h,2.26,83134,DB01171,Moclobemide
,2297459,percentages of,"The percentages of the dose excreted as moclobemide and Ro 12-8095 were (mean +/- s.d.) 0.057 +/- 0.020% and 0.031 +/- 0.011%, respectively.",Moclobemide excretion in human breast milk. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297459/),%,0.057,83135,DB01171,Moclobemide
,2297459,percentages of,"The percentages of the dose excreted as moclobemide and Ro 12-8095 were (mean +/- s.d.) 0.057 +/- 0.020% and 0.031 +/- 0.011%, respectively.",Moclobemide excretion in human breast milk. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2297459/),%,0.031,83136,DB01171,Moclobemide
,11422001,AUC,"Mean almotriptan AUC was higher (483 +/- 99.9 vs 352 +/- 75.4 ng ml-1 h, P = 0.0001) and oral clearance was lower (26.6 +/- 4.00 vs 36.6 +/- 5.89 l h-1, P = 0.0001) when almotriptan was administered with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),[h·ng] / [ml],483,90332,DB01171,Moclobemide
,11422001,AUC,"Mean almotriptan AUC was higher (483 +/- 99.9 vs 352 +/- 75.4 ng ml-1 h, P = 0.0001) and oral clearance was lower (26.6 +/- 4.00 vs 36.6 +/- 5.89 l h-1, P = 0.0001) when almotriptan was administered with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),[h·ng] / [ml],352,90333,DB01171,Moclobemide
,11422001,oral clearance,"Mean almotriptan AUC was higher (483 +/- 99.9 vs 352 +/- 75.4 ng ml-1 h, P = 0.0001) and oral clearance was lower (26.6 +/- 4.00 vs 36.6 +/- 5.89 l h-1, P = 0.0001) when almotriptan was administered with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),[l] / [h],26.6,90334,DB01171,Moclobemide
,11422001,oral clearance,"Mean almotriptan AUC was higher (483 +/- 99.9 vs 352 +/- 75.4 ng ml-1 h, P = 0.0001) and oral clearance was lower (26.6 +/- 4.00 vs 36.6 +/- 5.89 l h-1, P = 0.0001) when almotriptan was administered with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),[l] / [h],36.6,90335,DB01171,Moclobemide
,11422001,half-life,"Mean half-life was longer (4.22 +/- 0.78 vs 3.41 +/- 0.45 h, P = 0.0002) after coadministration with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),h,4.22,90336,DB01171,Moclobemide
,11422001,half-life,"Mean half-life was longer (4.22 +/- 0.78 vs 3.41 +/- 0.45 h, P = 0.0002) after coadministration with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),h,3.41,90337,DB01171,Moclobemide
,19925626,absolute bioavailability,The absolute bioavailability of subcutaneous (s.c.) sumatriptan is 96-100%.,Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925626/),%,96-100,95163,DB01171,Moclobemide
,19925626,T(max),"The decay curve for plasma concentration after 6 mg s.c. sumatriptan (ie, after T(max) = about 0.2 hours) includes a large distribution component.",Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925626/),h,0.2,95164,DB01171,Moclobemide
,19925626,AUC(0-10h),"At t = 10 hours, the concentrations in both sets were <1 ng/mL (ie, below the lower limit of assay quantitation), and AUC(0-10h) was 97.4 and 117 ng.",Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925626/),ng,97.4,95165,DB01171,Moclobemide
,19925626,AUC(0-10h),"At t = 10 hours, the concentrations in both sets were <1 ng/mL (ie, below the lower limit of assay quantitation), and AUC(0-10h) was 97.4 and 117 ng.",Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925626/),ng,117,95166,DB01171,Moclobemide
,30782258,bioavailability,"Furthermore, the extent of bioavailability (110.6 %) for the generic moclobemide tablets if compared to Aurorix tablets is not significantly different.",Bioavailability of moclobemide from two formulation tablets in healthy humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30782258/),%,110.6,97234,DB01171,Moclobemide
,2248087,absolute oral availability,The mean absolute oral availability was 0.66 and 0.69 respectively.,Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248087/),,0.66,105243,DB01171,Moclobemide
,2248087,absolute oral availability,The mean absolute oral availability was 0.66 and 0.69 respectively.,Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248087/),,0.69,105244,DB01171,Moclobemide
,2248087,accumulation factors,Mean accumulation factors for moclobemide during the first week were 1.85 for Cmax and 3.0 for AUC.,Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248087/),,1.85,105245,DB01171,Moclobemide
,2248087,accumulation factors,Mean accumulation factors for moclobemide during the first week were 1.85 for Cmax and 3.0 for AUC.,Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248087/),,3.0,105246,DB01171,Moclobemide
,1988238,systemic clearance,"The data on intravenous administration indicated that cimetidine produced a statistically significant alteration in the following disposition parameters (mean values for control versus cimetidine): systemic clearance, 46.6 versus 28.3 L/hr; mean residence time, 2.1 versus 3.2 hours; elimination half-life, 1.6 versus 2.3 hours.",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),[l] / [h],46.6,138863,DB01171,Moclobemide
,1988238,systemic clearance,"The data on intravenous administration indicated that cimetidine produced a statistically significant alteration in the following disposition parameters (mean values for control versus cimetidine): systemic clearance, 46.6 versus 28.3 L/hr; mean residence time, 2.1 versus 3.2 hours; elimination half-life, 1.6 versus 2.3 hours.",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),[l] / [h],28.3,138864,DB01171,Moclobemide
,1988238,mean residence time,"The data on intravenous administration indicated that cimetidine produced a statistically significant alteration in the following disposition parameters (mean values for control versus cimetidine): systemic clearance, 46.6 versus 28.3 L/hr; mean residence time, 2.1 versus 3.2 hours; elimination half-life, 1.6 versus 2.3 hours.",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),h,2.1,138865,DB01171,Moclobemide
,1988238,mean residence time,"The data on intravenous administration indicated that cimetidine produced a statistically significant alteration in the following disposition parameters (mean values for control versus cimetidine): systemic clearance, 46.6 versus 28.3 L/hr; mean residence time, 2.1 versus 3.2 hours; elimination half-life, 1.6 versus 2.3 hours.",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),h,3.2,138866,DB01171,Moclobemide
,1988238,elimination half-life,"The data on intravenous administration indicated that cimetidine produced a statistically significant alteration in the following disposition parameters (mean values for control versus cimetidine): systemic clearance, 46.6 versus 28.3 L/hr; mean residence time, 2.1 versus 3.2 hours; elimination half-life, 1.6 versus 2.3 hours.",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),h,1.6,138867,DB01171,Moclobemide
,1988238,elimination half-life,"The data on intravenous administration indicated that cimetidine produced a statistically significant alteration in the following disposition parameters (mean values for control versus cimetidine): systemic clearance, 46.6 versus 28.3 L/hr; mean residence time, 2.1 versus 3.2 hours; elimination half-life, 1.6 versus 2.3 hours.",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),h,2.3,138868,DB01171,Moclobemide
,1988238,absolute oral bioavailability,"The absolute oral bioavailability of moclobemide increased significantly after cimetidine administration (54% versus 68%), as did the maximum plasma concentration after a single oral dose (575 versus 787 ng/ml).",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),%,54,138869,DB01171,Moclobemide
,1988238,absolute oral bioavailability,"The absolute oral bioavailability of moclobemide increased significantly after cimetidine administration (54% versus 68%), as did the maximum plasma concentration after a single oral dose (575 versus 787 ng/ml).",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),%,68,138870,DB01171,Moclobemide
,1988238,maximum plasma concentration,"The absolute oral bioavailability of moclobemide increased significantly after cimetidine administration (54% versus 68%), as did the maximum plasma concentration after a single oral dose (575 versus 787 ng/ml).",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),[ng] / [ml],575,138871,DB01171,Moclobemide
,1988238,maximum plasma concentration,"The absolute oral bioavailability of moclobemide increased significantly after cimetidine administration (54% versus 68%), as did the maximum plasma concentration after a single oral dose (575 versus 787 ng/ml).",Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1988238/),[ng] / [ml],787,138872,DB01171,Moclobemide
,17141442,flow-rate,"The mobile phase consisted of 10 mM KH(2)PO(4) with 1% triethylamine (pH 3.9) and acetonitrile (83:17, v/v), and a flow-rate was 1.2 ml/min.",High-performance liquid chromatographic method for the determination of moclobemide and its two major metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17141442/),[ml] / [min],1.2,141905,DB01171,Moclobemide
,17141442,total run time,The total run time was 13 min.,High-performance liquid chromatographic method for the determination of moclobemide and its two major metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17141442/),min,13,141906,DB01171,Moclobemide
> or =,17141442,absolute recoveries,Mean absolute recoveries were > or =90% and the limit of quantification (LOQ) for all analytes was 0.02 mg/l.,High-performance liquid chromatographic method for the determination of moclobemide and its two major metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17141442/),%,90,141907,DB01171,Moclobemide
,19076986,AUC,"CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C(max) by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P < 0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P < 0.05) after 4 weeks of co-administration.",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[h·mg] / [l],7.794,141913,DB01171,Moclobemide
,19076986,AUC,"CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C(max) by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P < 0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P < 0.05) after 4 weeks of co-administration.",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[h·mg] / [l],5.038,141914,DB01171,Moclobemide
,19076986,C(max),"CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C(max) by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P < 0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P < 0.05) after 4 weeks of co-administration.",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[mg] / [l],1.911,141915,DB01171,Moclobemide
,19076986,C(max),"CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C(max) by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P < 0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P < 0.05) after 4 weeks of co-administration.",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[mg] / [l],1.383,141916,DB01171,Moclobemide
,19076986,oral clearance,"CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C(max) by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P < 0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P < 0.05) after 4 weeks of co-administration.",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[kg(-·l] / [h],0,141917,DB01171,Moclobemide
,19076986,through concentrations,"MCB through concentrations were also decreased, on average by 41% (from 0.950 to 0.559 mg l(-1); 95% CI -0.77479, -0.03301; P < 0.05).",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[mg] / [l],0.950,141918,DB01171,Moclobemide
,19076986,through concentrations,"MCB through concentrations were also decreased, on average by 41% (from 0.950 to 0.559 mg l(-1); 95% CI -0.77479, -0.03301; P < 0.05).",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[mg] / [l],0.559,141919,DB01171,Moclobemide
,1359056,clearance,"The average clearance in control rats (male and female) was 36 mL min-1 kg-1, the initial volume of distribution 1.4 L kg-1, the volume of distribution at steady state 2.3 L kg-1 and the terminal half-life 59 min.","Pharmacokinetics of moclobemide in male, virgin female, pregnant and nursing rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1359056/),[ml] / [kg·min],36,146709,DB01171,Moclobemide
,1359056,initial volume of distribution,"The average clearance in control rats (male and female) was 36 mL min-1 kg-1, the initial volume of distribution 1.4 L kg-1, the volume of distribution at steady state 2.3 L kg-1 and the terminal half-life 59 min.","Pharmacokinetics of moclobemide in male, virgin female, pregnant and nursing rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1359056/),[l] / [kg],1.4,146710,DB01171,Moclobemide
,1359056,volume of distribution at steady state,"The average clearance in control rats (male and female) was 36 mL min-1 kg-1, the initial volume of distribution 1.4 L kg-1, the volume of distribution at steady state 2.3 L kg-1 and the terminal half-life 59 min.","Pharmacokinetics of moclobemide in male, virgin female, pregnant and nursing rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1359056/),[l] / [kg],2.3,146711,DB01171,Moclobemide
,1359056,terminal half-life,"The average clearance in control rats (male and female) was 36 mL min-1 kg-1, the initial volume of distribution 1.4 L kg-1, the volume of distribution at steady state 2.3 L kg-1 and the terminal half-life 59 min.","Pharmacokinetics of moclobemide in male, virgin female, pregnant and nursing rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1359056/),min,59,146712,DB01171,Moclobemide
,1359056,blood-to-plasma concentration ratio,The blood-to-plasma concentration ratio of moclobemide was 0.84 giving rise to an average blood clearance of 30 mL min-1 kg-1.,"Pharmacokinetics of moclobemide in male, virgin female, pregnant and nursing rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1359056/),,0.84,146713,DB01171,Moclobemide
,1359056,blood clearance,The blood-to-plasma concentration ratio of moclobemide was 0.84 giving rise to an average blood clearance of 30 mL min-1 kg-1.,"Pharmacokinetics of moclobemide in male, virgin female, pregnant and nursing rats. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1359056/),[ml] / [kg·min],30,146714,DB01171,Moclobemide
,3283288,Tmax,"Bioavailability parameters obtained when drug was taken 30 min after the meal suggested that the rate of absorption was slightly decreased in the presence of food (mean Tmax 0.71 h vs. 1.14 h), while the extent of absorption of moclobemide given with food was unaltered.",Effect of food intake on the relative bioavailability of moclobemide (Ro 11-1163). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3283288/),h,0.71,147911,DB01171,Moclobemide
,3283288,Tmax,"Bioavailability parameters obtained when drug was taken 30 min after the meal suggested that the rate of absorption was slightly decreased in the presence of food (mean Tmax 0.71 h vs. 1.14 h), while the extent of absorption of moclobemide given with food was unaltered.",Effect of food intake on the relative bioavailability of moclobemide (Ro 11-1163). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3283288/),h,1.14,147912,DB01171,Moclobemide
,11966672,AUC,"The coadministration of moclobemide in EMs approximately doubled the mean AUC (from 1834 to 3760 ng ml(-1) h) and C(max) (from 987 to 1649 ng ml(-1)) of omeprazole, and increased the AUC of omeprazole sulphone without changing AUC ratio of omeprazole to omeprazole sulphone.",Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966672/),[h·ng] / [ml],1834,170216,DB01171,Moclobemide
,11966672,C(max),"The coadministration of moclobemide in EMs approximately doubled the mean AUC (from 1834 to 3760 ng ml(-1) h) and C(max) (from 987 to 1649 ng ml(-1)) of omeprazole, and increased the AUC of omeprazole sulphone without changing AUC ratio of omeprazole to omeprazole sulphone.",Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966672/),[ng] / [ml],987 to 1649,170217,DB01171,Moclobemide
,11966672,AUC ratio,"Moclobemide coadministration more than doubled the AUC ratio of omeprazole to 5-hydroxyomeprazole (from 2.5 to 5.3) in EMs, too.",Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966672/),,2.5,170218,DB01171,Moclobemide
,11966672,AUC ratio,"Moclobemide coadministration more than doubled the AUC ratio of omeprazole to 5-hydroxyomeprazole (from 2.5 to 5.3) in EMs, too.",Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11966672/),,5.3,170219,DB01171,Moclobemide
,7519866,maximum enzyme inhibition (IC50),"4. Plasma moclobemide concentrations associated with 50% of maximum enzyme inhibition (IC50) were in the range of 100 (IC50,5HIAA at 300 mg) to 400 micrograms l-1 (IC50,DHPG at 600 mg).","Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7519866/),[μg] / [l],100,192781,DB01171,Moclobemide
,7519866,IC50,"4. Plasma moclobemide concentrations associated with 50% of maximum enzyme inhibition (IC50) were in the range of 100 (IC50,5HIAA at 300 mg) to 400 micrograms l-1 (IC50,DHPG at 600 mg).","Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7519866/),[μg] / [l],100,192782,DB01171,Moclobemide
,7519866,IC50,"4. Plasma moclobemide concentrations associated with 50% of maximum enzyme inhibition (IC50) were in the range of 100 (IC50,5HIAA at 300 mg) to 400 micrograms l-1 (IC50,DHPG at 600 mg).","Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7519866/),[μg] / [l],400,192783,DB01171,Moclobemide
,2685852,fb,"However, a detailed comparison reveals a strong similarity between moclobemide and toloxatone (high hepatic extraction ratio; reduced oral bioavailability due to first-pass metabolism; similar binding to plasma protein, fb approximately 0.23).",[Pharmacokinetics and metabolism of reversible MAO-A inhibitors in the human]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685852/),,0.23,201560,DB01171,Moclobemide
,2685852,Elimination half-lives,"Elimination half-lives of 1-3 h for moclobemide and toloxatone contrast with the higher values for amiflamine (5-12 h), cimoxatone (9-16 h) and brofaromine (12-15 h).",[Pharmacokinetics and metabolism of reversible MAO-A inhibitors in the human]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685852/),h,1-3,201561,DB01171,Moclobemide
,2685852,Elimination half-lives,"Elimination half-lives of 1-3 h for moclobemide and toloxatone contrast with the higher values for amiflamine (5-12 h), cimoxatone (9-16 h) and brofaromine (12-15 h).",[Pharmacokinetics and metabolism of reversible MAO-A inhibitors in the human]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685852/),h,5-12,201562,DB01171,Moclobemide
,2685852,Elimination half-lives,"Elimination half-lives of 1-3 h for moclobemide and toloxatone contrast with the higher values for amiflamine (5-12 h), cimoxatone (9-16 h) and brofaromine (12-15 h).",[Pharmacokinetics and metabolism of reversible MAO-A inhibitors in the human]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685852/),h,9-16,201563,DB01171,Moclobemide
,2685852,Elimination half-lives,"Elimination half-lives of 1-3 h for moclobemide and toloxatone contrast with the higher values for amiflamine (5-12 h), cimoxatone (9-16 h) and brofaromine (12-15 h).",[Pharmacokinetics and metabolism of reversible MAO-A inhibitors in the human]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685852/),h,12-15,201564,DB01171,Moclobemide
,12190330,C(max),"Mean C(max) after a 20mg intranasal dose is approximately 13.1 to 14.4 ng/mL, with median time to C(max) approximately 1 to 1.75 hours.",Clinical pharmacokinetics of intranasal sumatriptan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12190330/),[ng] / [ml],13.1 to 14.4,207737,DB01171,Moclobemide
,12190330,time to C(max),"Mean C(max) after a 20mg intranasal dose is approximately 13.1 to 14.4 ng/mL, with median time to C(max) approximately 1 to 1.75 hours.",Clinical pharmacokinetics of intranasal sumatriptan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12190330/),h,1 to 1.75,207738,DB01171,Moclobemide
,12190330,elimination phase half-life,"The elimination phase half-life is approximately 2 hours, consistent with administration by other routes.",Clinical pharmacokinetics of intranasal sumatriptan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12190330/),h,2,207739,DB01171,Moclobemide
,2248061,peak concentration,The secondary amine metabolite Ro 16-3177 was found in rat plasma at all times investigated (up to 3 weeks); the peak concentration of 200 ng/ml was reached 15 min after administration of moclobemide.,Species-specific biotransformation of moclobemide: a comparative study in rats and humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248061/),[ng] / [ml],200,208777,DB01171,Moclobemide
,29079874,t 1/2,Pharmacokinetic in vivo investigation showed a rapid absorption of EMD386088 (2.5 and 5 mg/kg) with t 1/2 = 67 min (t max = 5 min).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),min,67,216604,DB01171,Moclobemide
,29079874,t max,Pharmacokinetic in vivo investigation showed a rapid absorption of EMD386088 (2.5 and 5 mg/kg) with t 1/2 = 67 min (t max = 5 min).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),min,5,216605,DB01171,Moclobemide
,29079874,volume of distribution (V d/F,Large volume of distribution (V d/F = 102 L/kg) indicated its penetration into peripheral compartments.,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),[l] / [kg],102,216606,DB01171,Moclobemide
,29079874,C max,The most active coadministration of EMD386088 (2.5 mg/kg) with imipramine (15 mg/kg) resulted in slower absorption of the compound (C max = 60 min) and decrease in the volume of distribution (V d/F = 32.2 L/kg).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),min,60,216607,DB01171,Moclobemide
,29079874,volume of distribution (V d/F,The most active coadministration of EMD386088 (2.5 mg/kg) with imipramine (15 mg/kg) resulted in slower absorption of the compound (C max = 60 min) and decrease in the volume of distribution (V d/F = 32.2 L/kg).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),[l] / [kg],32.2,216608,DB01171,Moclobemide
,29079874,brain/plasma ratio,EMD386088 penetrates the blood-brain barrier with a high brain/plasma ratio of about 19 (2.5 mg/kg) and 7.5 for coadministration with imipramine.,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),,19,216609,DB01171,Moclobemide
,29079874,brain/plasma ratio,EMD386088 penetrates the blood-brain barrier with a high brain/plasma ratio of about 19 (2.5 mg/kg) and 7.5 for coadministration with imipramine.,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),,7.5,216610,DB01171,Moclobemide
,29079874,IC 50,"EMD386088 did not influence on CYP3A4 activity, and it has been classified as a very weak CYP2D6 inhibitor (IC 50 = 2.25 μM).","Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),μM,2.25,216611,DB01171,Moclobemide
,15762767,half-life,The compound has a half-life of approximately 3 hours.,"Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15762767/),h,3,226151,DB01171,Moclobemide
,15762767,absolute bioavailability,Almotriptan is well absorbed after oral administration and the mean absolute bioavailability is 69.1%.,"Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15762767/),%,69.1,226152,DB01171,Moclobemide
,6538424,half-life t 1/2 beta,The drug was rapidly distributed into the tissue compartment and was then eliminated from the body with a mean half-life t 1/2 beta of about 1 h (range 0.79-1.34 h).,Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538424/),h,1,228199,DB01171,Moclobemide
,6538424,volume of distribution Vss,The volume of distribution Vss was of medium size (range 0.81-1.25 l/kg).,Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538424/),[l] / [kg],0.81-1.25,228200,DB01171,Moclobemide
,6538424,oral bioavailability,The oral bioavailability was reduced in consequence of the effect of the first passage through the liver and amounted to 44% on average (range 27-70%).,Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538424/),%,44,228201,DB01171,Moclobemide
within,6538424,tmax,"As to the drug absorption from the intestinal tract the extent and rate of this process were shown to be large (more than 95% absorbed on average, tmax-values within 1 h).",Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6538424/),h,1,228202,DB01171,Moclobemide
,7725375,half-life,"After concentration decrease with time was taken into account (average half-life estimate of 4.6 h), age was identified as a major factor responsible for between-patient variability.",Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7725375/),h,4.6,239962,DB01171,Moclobemide
,3665338,clearance,"The disposition values (percent coefficient of variation in parentheses) after the first and second intravenous infusions, respectively, were: clearance, 39.4 (15%) and 29.1 (12%) L/hr; elimination half-life, 1.60 (15%) and 2.00 (18%) hours; and volume of distribution at steady state, 84.3 (11%) and 80.7 (15%) L.","Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665338/),[l] / [h],39.4,262357,DB01171,Moclobemide
,3665338,clearance,"The disposition values (percent coefficient of variation in parentheses) after the first and second intravenous infusions, respectively, were: clearance, 39.4 (15%) and 29.1 (12%) L/hr; elimination half-life, 1.60 (15%) and 2.00 (18%) hours; and volume of distribution at steady state, 84.3 (11%) and 80.7 (15%) L.","Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665338/),[l] / [h],29.1,262358,DB01171,Moclobemide
,3665338,elimination half-life,"The disposition values (percent coefficient of variation in parentheses) after the first and second intravenous infusions, respectively, were: clearance, 39.4 (15%) and 29.1 (12%) L/hr; elimination half-life, 1.60 (15%) and 2.00 (18%) hours; and volume of distribution at steady state, 84.3 (11%) and 80.7 (15%) L.","Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665338/),h,1.60,262359,DB01171,Moclobemide
,3665338,elimination half-life,"The disposition values (percent coefficient of variation in parentheses) after the first and second intravenous infusions, respectively, were: clearance, 39.4 (15%) and 29.1 (12%) L/hr; elimination half-life, 1.60 (15%) and 2.00 (18%) hours; and volume of distribution at steady state, 84.3 (11%) and 80.7 (15%) L.","Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665338/),h,2.00,262360,DB01171,Moclobemide
,3665338,volume of distribution at steady state,"The disposition values (percent coefficient of variation in parentheses) after the first and second intravenous infusions, respectively, were: clearance, 39.4 (15%) and 29.1 (12%) L/hr; elimination half-life, 1.60 (15%) and 2.00 (18%) hours; and volume of distribution at steady state, 84.3 (11%) and 80.7 (15%) L.","Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665338/),l,84.3,262361,DB01171,Moclobemide
,3665338,volume of distribution at steady state,"The disposition values (percent coefficient of variation in parentheses) after the first and second intravenous infusions, respectively, were: clearance, 39.4 (15%) and 29.1 (12%) L/hr; elimination half-life, 1.60 (15%) and 2.00 (18%) hours; and volume of distribution at steady state, 84.3 (11%) and 80.7 (15%) L.","Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665338/),l,80.7,262362,DB01171,Moclobemide
,3665338,absolute oral bioavailability,"The absolute oral bioavailability increased from 0.56 after the first oral dose to 0.86 and 0.90 after the first and second weeks of administration, respectively.","Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665338/),,0.56,262363,DB01171,Moclobemide
,3665338,absolute oral bioavailability,"The absolute oral bioavailability increased from 0.56 after the first oral dose to 0.86 and 0.90 after the first and second weeks of administration, respectively.","Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665338/),,0.86,262364,DB01171,Moclobemide
,3665338,absolute oral bioavailability,"The absolute oral bioavailability increased from 0.56 after the first oral dose to 0.86 and 0.90 after the first and second weeks of administration, respectively.","Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665338/),,0.90,262365,DB01171,Moclobemide
,1304448,FBL,Similar FBL values were observed in both groups (group A vs B): during the first week the FBL values were (mean +/- SD) 0.40 +/- 0.23 ml/day vs 0.55 +/- 0.53 ml/day on days 1-3 and 0.40 +/- 0.21 ml/day vs 0.37 +/- 0.13 ml/day on days 4-7.,Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304448/),[ml] / [d],0.40,274100,DB01171,Moclobemide
,1304448,FBL,Similar FBL values were observed in both groups (group A vs B): during the first week the FBL values were (mean +/- SD) 0.40 +/- 0.23 ml/day vs 0.55 +/- 0.53 ml/day on days 1-3 and 0.40 +/- 0.21 ml/day vs 0.37 +/- 0.13 ml/day on days 4-7.,Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304448/),[ml] / [d],0.55,274101,DB01171,Moclobemide
,1304448,FBL,Similar FBL values were observed in both groups (group A vs B): during the first week the FBL values were (mean +/- SD) 0.40 +/- 0.23 ml/day vs 0.55 +/- 0.53 ml/day on days 1-3 and 0.40 +/- 0.21 ml/day vs 0.37 +/- 0.13 ml/day on days 4-7.,Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304448/),[ml] / [d],0.40,274102,DB01171,Moclobemide
,1304448,FBL,Similar FBL values were observed in both groups (group A vs B): during the first week the FBL values were (mean +/- SD) 0.40 +/- 0.23 ml/day vs 0.55 +/- 0.53 ml/day on days 1-3 and 0.40 +/- 0.21 ml/day vs 0.37 +/- 0.13 ml/day on days 4-7.,Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304448/),[ml] / [d],0.37,274103,DB01171,Moclobemide
,1304448,FBL,"The increase in FBL during the second week was comparable in both groups, with and without moclobemide (days 8-10: 0.78 +/- 0.59 ml/day vs 0.80 +/- 0.58 ml/day; days 11-14: 1.49 +/- 0.95 ml/day vs 1.28 +/- 0.62 ml/day).",Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304448/),[ml] / [d],0.78,274104,DB01171,Moclobemide
,1304448,FBL,"The increase in FBL during the second week was comparable in both groups, with and without moclobemide (days 8-10: 0.78 +/- 0.59 ml/day vs 0.80 +/- 0.58 ml/day; days 11-14: 1.49 +/- 0.95 ml/day vs 1.28 +/- 0.62 ml/day).",Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304448/),[ml] / [d],0.80,274105,DB01171,Moclobemide
,1304448,FBL,"The increase in FBL during the second week was comparable in both groups, with and without moclobemide (days 8-10: 0.78 +/- 0.59 ml/day vs 0.80 +/- 0.58 ml/day; days 11-14: 1.49 +/- 0.95 ml/day vs 1.28 +/- 0.62 ml/day).",Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304448/),[ml] / [d],1.49,274106,DB01171,Moclobemide
,1304448,FBL,"The increase in FBL during the second week was comparable in both groups, with and without moclobemide (days 8-10: 0.78 +/- 0.59 ml/day vs 0.80 +/- 0.58 ml/day; days 11-14: 1.49 +/- 0.95 ml/day vs 1.28 +/- 0.62 ml/day).",Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1304448/),[ml] / [d],1.28,274107,DB01171,Moclobemide
